Biography:Philip Seeman
 | This article is an autobiography or has been extensively edited by the subject or by someone connected to the subject. (February 2013) (Learn how and when to remove this template message) |
Philip Seeman | |
|---|---|
| Born | 8 February 1934 Winnipeg, Manitoba, Canada |
| Died | 9 January 2021 (aged 86) Toronto, Ontario, Canada |
| Awards | Order of Canada |
Philip Seeman, OC FRSC (8 February 1934 – 9 January 2021) was a Canadian schizophrenia researcher and neuropharmacologist, known for his research on dopamine receptors.[1]
Career
Born in Winnipeg, Manitoba, Seeman was raised in Montreal . He received a Bachelor of Science degree, honours physics & physiology (1955), a Master of Science degree, physiology of transport & secretion (1956), and a Doctor of Medicine (1960) from McGill University. In 1966, he received a Ph.D. in life sciences from Rockefeller University.
In 1967, Seeman became an assistant professor in the Department of Pharmacology at the University of Toronto. In 1970, he was appointed a professor.
In 1974, having spent years in search of the binding site of antipsychotic medication, he discovered the dopamine D2 receptor, the basis for the dopamine hypothesis of schizophrenia.[2][3]
In 2001, he was made an Officer of the Order of Canada "for his research on dopamine receptors and their involvement in diseases such as schizophrenia, Parkinson's and Huntington's".[4]
In 1985, he was made a Fellow of the Royal Society of Canada.[5]
He was married to Dr. Mary V. Seeman.[6]
Notes
- ↑ "Philip SEEMAN". The Globe and Mail. https://www.legacy.com/obituaries/theglobeandmail/obituary.aspx?n=philip-seeman&pid=197516322.
- ↑ P. Seeman, M. Chau-Wong, J. Tedesco & K. Wong (November 1975). "Brain receptors for antipsychotic drugs and dopamine: direct binding assays". Proceedings of the National Academy of Sciences of the United States of America 72 (11): 4376–4370. doi:10.1073/pnas.72.11.4376. PMID 1060115. Bibcode: 1975PNAS...72.4376S.
- ↑ "People". CMAJ 151 (8): 1186–1187. 1994.
- ↑ Order of Canada citation
- ↑ "Science & Medicine - Science & Medicine". http://www.sciandmed.com/sm/journalviewer.aspx?issue=1066&article=787&action=1.
- ↑ "Most Wikipedia profiles are about men – these women in Australia are hoping to change that" (in en). SBS News. https://www.sbs.com.au/news/most-wikipedia-profiles-are-about-men-these-women-in-australia-are-hoping-to-change-that.
References
- Madras, B.K. (2013). "History of the discovery of the antipsychotic dopamine D2 receptor: A basis for the dopamine hypothesis of schizophrenia". Journal of the History of the Neurosciences: Basic and Clinical Perspectives 22 (1): 62–78. doi:10.1080/0964704x.2012.678199. PMID 23323533.
- Seeman, P. (2011). "All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors". CNS Neuroscience & Therapeutics 17 (2): 118–132. doi:10.1111/j.1755-5949.2010.00162.x. PMID 20560996.
- P. Seeman (2010). "Dopamine D2 Receptors as Treatment Targets in Schizophrenia. Clinical Schizophrenia & Related Psychoses April: 56-73.
- P. Seeman (2007), Scholarpedia, 2(10): 3634 doi.4249/scholarpedia.3634
- Seeman, P. (2006). "Targeting the dopamine D2 receptor in schizophrenia". Expert Opinion on Therapeutic Targets 10 (4): 515–531. doi:10.1517/14728222.10.4.515. PMID 16848689.
- Seeman, P.; Weinshenker, D.; Quirion, R.; Srivastava, L.; Bhardwaj, S.K.; Grandy, D.K.; Premont, R.; Sotnikova, T. et al. (2005). "Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis". Proceedings of the National Academy of Sciences USA 102 (9): 3513–3518. doi:10.1073/pnas.0409766102. PMID 15716360. Bibcode: 2005PNAS..102.3513S.
- Seeman, P.; Chau-Wong, M.; Tedesco, J.; Wong, K. (1975). "Brain receptors for antipsychotic drugs and dopamine: Direct binding assays". Proceedings of the National Academy of Sciences, USA 72 (11): 4376–4380. doi:10.1073/pnas.72.11.4376. PMID 1060115. Bibcode: 1975PNAS...72.4376S.
External links
- Home Page of Philip Seeman's Laboratory
- Probing the Biology of Psychosis, Schizophrenia, and Antipsychotics: An Expert Interview With Dr. Philip Seeman, MD, PhD – an interview on the Medscape website
- Schizophrenia – an essay by Philip Seeman, November 2001
 |  |
